Epoch Biodesign

Executive Summary

Epoch Biodesign is a UK-based synthetic biology company tackling the global plastic waste crisis by engineering enzymes and microbial systems to break down persistent plastics like PET. Founded in 2021 and headquartered in Manchester, the company uses a proprietary metabolic engineering platform to design novel biological pathways that convert plastic pollutants into valuable, reusable chemical feedstocks. This approach offers a sustainable circular economy solution, turning waste into resources while reducing environmental harm. Epoch's technology targets the enormous challenge of plastic pollution, which traditional recycling methods struggle to address effectively, especially for mixed or contaminated waste streams. The company is currently in the platform stage, with a small team (1–50 employees) and is privately held. While specific funding details are undisclosed, the company is likely pursuing or planning a Series A round to scale its R&D and pilot its technology. Epoch's potential lies in its ability to provide a scalable, biological route for plastic degradation, complementing chemical recycling methods. If successful, the company could become a key player in the emerging bio-economy for plastics, with applications spanning waste management, chemical manufacturing, and consumer goods. Near-term catalysts include financing milestones, research breakthroughs, and strategic partnerships that could accelerate its path to commercial validation.

Upcoming Catalysts (preview)

• Q1 2027Series A Funding Announcement60% success
• Q3 2026Proof-of-Concept Publication or Pilot Project with Waste Management Partner50% success
• Q4 2026Enzyme Efficiency Breakthrough Revealed in Preprint or Conference40% success